MorphoSys AG
MorphoSys AG (MPSYF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mpsyf · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for MorphoSys AG (MPSYF) measures how much investors pay for each dollar of the company's trailing earnings. MPSYF's current PE ratio of N/A is calculated by dividing its stock price of $73.27 by its TTM earnings per share of -$1.38.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2004 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 12 fiscal years · Front-end computedMinQ1 · 25%52.2x
MedianQ3 · 75%845.5x
Max
At N/A, MPSYF's current P/E is lower than in 0% of its annual fiscal year readings over the past 12 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
MorphoSys AGYou MPSYF | $2.8B | N/A | — | -$1.38 |
 Alfresa Holdings Corporation ARHCF | $2.2B | 8.15x | -67.1% | $231.09 |
 Ascentage Pharma Group International ASPHF | $1.7B | N/A | — | -$3.40 |
 Biotest AG BIESF | $1.6B | 41.48x | +67.1% | $0.71 |
 Indivior PLC INVVY | $3.0B | N/A | — | -$0.38 |
 Indivior PLC IZQVF | $2.9B | N/A | — | — |
 Mithra Pharmaceuticals S.A. MITPF | $1.6B | N/A | — | -$2.51 |
Industry Average 2 peers with valid PE | — | 24.81x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-5.53 | — | |
2022-12-31 FY2022 | — | $-4.42 | — | |
2021-12-31 FY2021 | — | $-15.40 | — | |
2020-12-31 FY2020 | 30.76x | $3.01 | — | |
2019-12-31 FY2019 | — | $-3.26 | — | |
2018-12-31 FY2018 | — | $-1.79 | — | |
2017-12-31 FY2017 | — | $-2.41 | — | |
2016-12-31 FY2016 | — | $-2.28 | — | |
2015-12-31 FY2015 | 100.32x | $0.57 | — | |
2014-12-31 FY2014 | — | $-0.12 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for MorphoSys AG (MPSYF) measures how much investors pay for each dollar of the company's trailing earnings. MPSYF's current PE ratio of N/A is calculated by dividing its stock price of $73.27 by its TTM earnings per share of -$1.38.
Frequently asked questions
MPSYF pe ratio · 6 questionsMPSYF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $73.27 and TTM EPS of -$1.38. Data sourced from Financial Modeling Prep via MPSYF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MorphoSys AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08